Who We Are
What We Do
How We Do It
Where We Do It
Value, Access, and Pricing
A new economic era is dawning, and understanding how value can best support price and access will be essential to the success of future and current brands.
From new modes of administration to new mechanisms of action, specialty therapeutic landscapes are crowding with new dimensions of competition. Understanding local market perceptions and behaviours are just the beginning to developing a sound commercial strategy with the expertise of CBPartners’ team.
As market and payer realities evolve, it will be essential to adapt to meet new stakeholder needs, as well as to understand the value of that adaptation.
Government Policy Advisory
The world’s landscape is quickly evolving due to both innovation and government policy. Ensuring that these policies match political and commercial goals is possible through the expertise of CBPartners’ team.
Vermont’s Drug Importation: Rubber, Meet Road
21 February 2019
CHINA: Awakening the Pharmaceutical Innovation Giant
14 January 2019
Evolving Reimbursement Dynamics in China
9 September 2018
Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?
17 August 2018
Cell and Gene Therapies: Paving the Commercial Pathways of Tomorrow
25 April 2018
CAR-T Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome
5 March 2018
WHO Stands to Benefit the most from the Biosimilars Prequalification Programme?
22 November 2017
View All Blog Posts
ISPOR International: Times That Try Souls
07 July 2017
Cyrus A. Chowdhury
Sandeep Duttagupta, PhD
ISPOR BOSTON: Pharmaceutical Strategic Pricing: An Analysis of Global Cross-SKU Pricing Approaches
ISPOR BOSTON: The Effectiveness of the FDA Priority Review Voucher for Neglected Tropical Diseases and Rare Pediatric Diseases
ISPOR BOSTON: Risk-Sharing Agreements (RSA) in Emerging Markets: Is it a Wake-Up Call or is it Innovation Too Late?
ISPOR BOSTON: How the Purchase and Use of a FDA Priority Review Voucher Affects Product Uptake and Value Conversion
Forecasting Failure: Learning from the Accuracy of Hindsight
ISPOR Asia 2016: Taming Enthusiasm
View All White Papers